公开(公告)号：US11944644B2

公开(公告)日：2024-04-02

申请号：US16769111

申请日：2018-12-04

Applicant: THE MEDICAL RESEARCH INFRASTRUCTURE AND HEALTH SERVICES FUND OF THE TEL AVIV MEDICAL CENTER ,  YEDA RESEARCH AND DEVELOPMENT CO. LTD.

Inventor： Zelig Eshhar ,  Tova Waks ,  Anat Globerson Levin ,  Moran Rawet Slobodkin

IPC: A61K39/00 ,  A61K35/17 ,  A61K39/395 ,  A61P35/00 ,  C07K16/28 ,  C07K16/30 ,  C12N5/0783 ,  C12N5/10 ,  C12N15/63

CPC classification number: A61K35/17 ,  A61K39/001126 ,  A61K39/001129 ,  A61K39/3955 ,  A61K39/39558 ,  A61K39/4631 ,  A61P35/00 ,  C07K16/28 ,  C07K16/2896 ,  C07K16/3061 ,  C12N5/0636 ,  C12N5/10 ,  C12N15/63 ,  A61K2039/505 ,  C07K16/30 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/56 ,  C07K2317/569 ,  C07K2317/76 ,  C07K2319/03

Abstract: The present invention provides T-cells expressing at least two different chimeric antigen receptors, wherein one of the CARs binds specifically to CD138 and another CAR binds specifically to CD38. In particular, the present invention provides T-cells expressing two different CARs, when one CAR comprises anti-CD138 sc Fv and the second CAR anti-CD138 sc Fv. Further, the invention provides a pharmaceutical composition comprising these dual CAR T-cells and their use in treatment of cancer, in particular multiple myeloma, and methods for preparation of these cells.

公开(公告)号：US20140336105A1

公开(公告)日：2014-11-13

申请号：US14323408

申请日：2014-07-03

Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.

Inventor： Yechiel Shai ,  Avner Fink ,  Shay Yaari ,  Tova Waks ,  Zelig Eshhar ,  Christopher J. Arnush

IPC: C07K7/08 ,  C07K14/00

CPC classification number: C07K7/08 ,  A61K38/08 ,  C07K7/00 ,  C07K14/001

Abstract: Anti-inflammatory peptides and pharmaceutical compositions including lysine, alanine, leucine and/or valine for treating inflammatory conditions and uses thereof. Anti-inflammatory peptides for treating IgE-mediated allergies and inflammatory conditions caused by a microbial infection including but not limited to sepsis.

Abstract translation: 抗炎肽和药物组合物，包括用于治疗炎性病症的赖氨酸，丙氨酸，亮氨酸和/或缬氨酸及其用途。 用于治疗由微生物感染引起的IgE介导的过敏和炎性病症的抗炎肽，包括但不限于败血症。

公开(公告)号：US09623049B2

公开(公告)日：2017-04-18

申请号：US13669194

申请日：2012-11-05

Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.

Inventor： Zelig Eshhar ,  Assaf Marcus ,  Tova Waks

IPC: A61K35/26 ,  A61K35/28 ,  A61K38/00 ,  A61K35/17 ,  A61K31/137 ,  A61K31/197 ,  A61K31/4245 ,  C12N5/0783 ,  A61K31/135 ,  A61K31/185 ,  A61K31/196 ,  A61K31/661 ,  A61K31/675 ,  A61K31/7076 ,  A61K39/395 ,  A61K47/48 ,  A61K48/00 ,  A61N5/10 ,  B82Y5/00 ,  A61K35/12

CPC classification number: A61K35/17 ,  A61K31/135 ,  A61K31/137 ,  A61K31/185 ,  A61K31/196 ,  A61K31/197 ,  A61K31/4245 ,  A61K31/661 ,  A61K31/675 ,  A61K31/7076 ,  A61K39/39541 ,  A61K47/6891 ,  A61K48/00 ,  A61K2035/124 ,  A61N5/10 ,  B82Y5/00 ,  C07K16/32 ,  C07K2317/24 ,  C07K2317/622 ,  C07K2317/732 ,  C12N5/0636 ,  C12N5/0638 ,  C12N2501/2302 ,  C12N2501/50 ,  C12N2501/51 ,  C12N2501/515 ,  C12N2501/59 ,  C12N2501/599 ,  C12N2510/00

Abstract: A method of treating a disease, such as cancer, by administering to a subject in need of such treatment an effective amount of allogeneic T cells with a MHC unrestricted chimeric receptor short time after partial lymphodepletion. The method also comprises administering one or more agents that delay egression of the allogeneic T cells from lymph nodes of said subject during adoptive transfer of said allogeneic T cells to the subject by trapping the T cells in the lymph nodes.

公开(公告)号：US12139522B2

公开(公告)日：2024-11-12

申请号：US16769867

申请日：2018-12-04

Applicant: THE MEDICAL RESEARCH INFRASTRUCTURE AND HEALTH SERVICES FUND OF THE TEL AVIV MEDICAL CENTER ,  YEDA RESEARCH AND DEVELOPMENT CO. LTD.

Inventor： Zelig Eshhar ,  Tova Waks ,  Anat Globerson Levin ,  Naamit Deshet-Unger ,  Moran Rawet Slobodkin ,  Dan Grisaru ,  Ben Zion Katz ,  Ido Laskov

IPC: C07K14/725 ,  A61K35/17 ,  C07K16/28 ,  C07K16/32 ,  A61K38/00

Abstract: The present invention provides T-cells modified to express at least two chimeric antigen receptors, wherein one of the CARs binds specifically to an antigen selected from CD138, HER2 and CD24 and another CAR binds specifically a different antigen selected from CD 138, HER2 and CD24. Further, the invention provides pharmaceutical compositions comprising these CAR T-cells and their use in treatment of cancer, in particular, ovarian cancer, DNA constructs encoding said CARs and methods for preparation of T-cells expressing said CARs.

公开(公告)号：US11932871B2

公开(公告)日：2024-03-19

申请号：US16490568

申请日：2018-03-02

Applicant: Yeda Research and Development Co. Ltd. ,  The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center

Inventor： Benjamin Geiger ,  Nir Friedman ,  Shimrit Lieber ,  Zelig Eshhar ,  Tova Waks ,  Anat Globerson Levin

IPC: C12N5/0783 ,  A61K35/17

CPC classification number: C12N5/0636 ,  A61K35/17 ,  C12N2501/21 ,  C12N2501/2306 ,  C12N2501/515 ,  C12N2501/58 ,  C12N2502/1121 ,  C12N2510/00

Abstract: Methods of culturing T cells are provided. Accordingly there is provided a method of culturing T cells comprising culturing T cells in the presence of a T cell stimulator, an exogenous CCL21 and an exogenous ICAM1, thereby culturing the T cells. Also provided are cell cultures, isolated T cells and uses of same.

公开(公告)号：US09346854B2

公开(公告)日：2016-05-24

申请号：US14323408

申请日：2014-07-03

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Yechiel Shai ,  Avner Fink ,  Shay Yaari ,  Tova Waks ,  Zelig Eshhar ,  Christopher J. Arnush

IPC: C07K7/00 ,  C07K7/08 ,  A61K38/08 ,  C07K14/00

CPC classification number: C07K7/08 ,  A61K38/08 ,  C07K7/00 ,  C07K14/001

Abstract: Isolated peptides of 13-30 amino acids comprising 5-9 consecutive repeats of the amino acid pair Alanine-Leucine or Alanine-Valine are provided. The peptides further comprise a stretch of 1-3 Lysine residues present at least at one of the peptide's termini, wherein the only Lysine residue in the isolated peptide is present at the stretch of 1-3 Lysine residues. Pharmaceutical compositions comprising same, methods of treating inflammatory conditions and allergic reactions, as well as methods of neutralizing the activity of lypopolysaccharides are also provided.

Abstract translation: 提供了包含氨基酸对丙氨酸 - 亮氨酸或丙氨酸 - 缬氨酸的5-9个连续重复的13-30个氨基酸的分离的肽。 所述肽还包含存在于至少一个肽末端的1-3个赖氨酸残基，其中分离的肽中唯一的赖氨酸残基以1-3个赖氨酸残基的一段存在。 还提供了包含其的药物组合物，治疗炎性病症和过敏反应的方法，以及中和赖福多糖活性的方法。